RecruitingNCT06547099

Study to Understand Novel Biomarkers in Researching Dementia

Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis

Sponsor

Washington University School of Medicine

Enrollment

1,800 participants

Start Date

Aug 14, 2024

Study Type

OBSERVATIONAL

Conditions

Dementia Alzheimer Disease Mild Cognitive Impairment

Summary

The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study (called SEABIRD) is researching new blood-based biomarkers — measurable substances in the blood — that may help detect dementia and Alzheimer's disease earlier and track its progression over time. **You may be eligible if...** - You are at least 60 years old - You have symptoms of memory loss, mild cognitive impairment, or early dementia, OR you have normal memory and are willing to serve as a comparison participant - You are already being seen at a participating memory or neurology clinic **You may NOT be eligible if...** - You cannot perform basic activities of daily living (eating, bathing, dressing, walking, toileting) on your own due to cognitive impairment - You have uncontrolled hepatitis B, hepatitis C, or HIV - You are currently taking a disease-modifying drug for Alzheimer's disease - You have had a blood transfusion in the last 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.